TARS: Tarsus Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TARS: Tarsus Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,877.41
Enterprise Value ($M) 1,854.44
Book Value ($M) 224.53
Book Value / Share 5.85
Price / Book 8.36
NCAV ($M) 204.25
NCAV / Share 5.32
Price / NCAV 9.19

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.33
Return on Equity (ROE) -0.42

Liquidity (mrq)
Quick Ratio 4.39
Current Ratio 4.42

Balance Sheet (mrq) ($M)
Current Assets 356.70
Assets 376.99
Liabilities 152.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 182.95
Operating Income -120.57
Net Income -115.55

Cash Flow Statement (mra) ($M)
Cash From Operations -83.03
Cash from Investing -199.19
Cash from Financing 154.66

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Cowen Financial Products LLC 4.90 -0.11
11-14 13G/A Cormorant Asset Management, LP 1.31 -77.49
11-14 13G/A Paradigm Biocapital Advisors LP 6.40 26.61
11-14 13G Prudential Financial Inc 6.00
11-12 13G Jennison Associates Llc 5.70
11-12 13G/A Vanguard Group Inc 5.51 0.00
11-08 13G/A BlackRock, Inc. 9.90 0.00
11-06 13G/A Frazier Life Sciences IX, L.P. 4.20 12.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-02 171,065 525,091 32.58
2025-04-01 159,305 520,384 30.61
2025-03-31 142,661 411,523 34.67
2025-03-28 143,916 444,198 32.40

(click for more detail)

Similar Companies
SVRA – Savara Inc. SWTX – SpringWorks Therapeutics, Inc.
SYRE – Spyre Therapeutics, Inc. TECH – Bio-Techne Corporation
TERN – Terns Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io